cynoGPC1-HEK293 is used in biomedical research, particularly in the development and testing of monoclonal antibodies and immunotherapies targeting the GPC1 (glypican-1) protein. It serves as a cellular assay system to evaluate binding specificity and functional activity of therapeutic candidates in preclinical studies. Due to its expression in HEK293 cells, it provides a stable and reproducible platform for high-throughput screening, antibody validation, and pharmacokinetic assessments. This system is especially valuable in oncology research, where GPC1 is investigated as a biomarker and therapeutic target in solid tumors such as pancreatic and breast cancer.